Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30536587 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL26858881 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL26858898 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL29036740 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL29456583 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL30536585 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL25253765 | 0.90 | KDM4E (0.43) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL25295894 | 0.90 | KDM4E (0.43) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL25295895 | 0.90 | KDM4E (0.43) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL22894679 | 0.87 | S1PR4 (0.50) | KDM4EALDH1A1KMT2ASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552808-B2 | Diol desymmetrization by nucleophilic aromatic substitution | AMGEN INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4208467-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | Amgen Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022051317-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | AMGEN INC. (US) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552808-B2 | Diol desymmetrization by nucleophilic aromatic substitution | MCL1, BAK1, BCL2 | KDM4E 3370/4885ALDH1A1 1597/4885KMT2A 2283/4885 |
| US-20230365588-A1 | DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION | MCL1, BAK1, BCL2A1 | KDM4E 1125/4885ALDH1A1 393/4885KMT2A 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.